東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁 到查詢結果 [ subject:"Positron-Emission Tomography." ]

切換: 標籤 | MARC模式 | ISBD

Trends on the role of PET in drug de...

Elsinga, Philip H.

FindBook

Google Book

Amazon

博客來

Trends on the role of PET in drug development

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Trends on the role of PET in drug development/ Philip H. Elsinga.
作者:	Elsinga, Philip H.
其他作者:	Van Waarde, Aren.
出版者:	Singapore :World Scientific, : 2012.,
面頁冊數:	1 online resource (799 p.)
附註:	2.2 Influence of ionic liquid and tertiary alcohols on [18F]fluorination.
內容註:	The Editors; Contributors; Preface; 1 Introduction on PET. Description of Basics and Principles Aren van Waarde; References; 2 Drug Development in the Pharmaceutical Industry Adrian D. Nunn; 1. Introduction; 2. Drug Approval Rates; 3. Costs of Each Stage; 4. Efficiency of Drug Development; 5. Changing Healthcare Model; 6. Comparative Effectiveness; 7. Personalized Medicine; 8. Regulatory Issues; 9. Conclusions; References; 3 Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines R. Paul Maguire; 1. Summary.
內容註:	2. FDA Critical Path Initiative -- Drug Development Challenge3. Drug Development Process Decision Points; 3.1 Phases of drug development; 4. Imaging Biomarkers in General; 4.1 Imaging biomarkers for early decision making; 4.2 Diagnostics; 4.2.1 Smaller likelihood ratio; 4.3 Markers of disease; 5. Imaging Biomarkers Other than Molecular Imaging; 6. Biomarkers Other than Imaging; 7. Receptor Occupancy; 7.1 Determination of in vivo KD; 7.2 Typical RO study designs; 7.3 Assumptions; 8. Thresholds for Decision Making; 8.1 Efficacy and occupancy at G-coupled protein receptors.
內容註:	9. Sources of Imprecision9.1 Instrument sensitivity; 9.2 Variability of PK; 10. Safety of Molecular Imaging Probes; 11. Ideal Molecular Imaging Ligand; 11.1 Safety; 11.2 Affinity; 11.3 Non-specific binding; 11.4 Selectivity; 11.5 Easy deployment and implementation; 12. Models of PET-Pharmacokinetics -- Data Analysis; 13. Industry Academic Collaboration; 13.1 Labeling available chemical matter; 13.2 Translational imaging; 13.3 Customized therapies -- companion diagnostics; 14. Summary; References; 4 What is the Role of Positron Emission Tomography in Drug Development? Timothy J. McCarthy.
內容註:	1. Introduction2. Biomarker Definitions; 3. PET as a Tool for Proof of Target; 4. PET as a Tool for Proof of Mechanism; 5. PET as a Tool for Proof of Efficacy; 6. Summary and Conclusions; References; 5 Review of 11C Preparations and Examples in Drug Development Farhad Karimi and Bengt Långstrom; 1. Choice of Radionuclide; 2. 11C Compounds; 2.1 11C precursor; 2.2 11C chemistry based on [11C]methyl iodide/triflate; 2.2.1 Palladium-mediated C-C bond formation; 2.3 11C Chemistry based on [11C]carbon monoxide; 2.3.1 [11C]Carbon monoxide insertion.
內容註:	2.3.2 Organo metals mediated 11C-carbonylation reaction2.3.2.1 Palladium-mediated 11C-carbonylation reaction; 2.3.2.2 Selenium-mediated 11C-carbonylation reaction; 2.3.2.3 Rhodium-mediated 11C-carbonylation reaction; 2.3.2.4 Radical-mediated carbonylation reactions; 3. Endogenous PET-Radiopharmaceuticals; 4. Automated Synthetic Devices; References; 6 The Role of Recent Development of 18F Radiochemistry in Drug Development Farhad Karimi and Bengt Långstrom; 1. Introduction; 2. Nucleophilic 18F Fluorination; 2.1 Basic chemistry.
標題:	Drug Design. -
電子資源:	http://www.worldscientific.com/worldscibooks/10.1142/7851#t=toc
ISBN:	9789814317740 (electronic bk.)

Trends on the role of PET in drug development
Elsinga, Philip H.

Trends on the role of PET in drug development[electronic resource] /Philip H. Elsinga. - Singapore :World Scientific,2012. - 1 online resource (799 p.)

2.2 Influence of ionic liquid and tertiary alcohols on [18F]fluorination.

The Editors; Contributors; Preface; 1 Introduction on PET. Description of Basics and Principles Aren van Waarde; References; 2 Drug Development in the Pharmaceutical Industry Adrian D. Nunn; 1. Introduction; 2. Drug Approval Rates; 3. Costs of Each Stage; 4. Efficiency of Drug Development; 5. Changing Healthcare Model; 6. Comparative Effectiveness; 7. Personalized Medicine; 8. Regulatory Issues; 9. Conclusions; References; 3 Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines R. Paul Maguire; 1. Summary.

Drug development is very expensive and a fight against time. PET offers possibilities to speed up this process by adding unique in vivo information on pharmacokinetics/dynamics of a drug at an early stage. This information can help decision makers to move the drug in the drug development process or to decide to stop further developments. This unique and complete book highlights the different ways PET can be used and describes the latest trends in the various disciplines within nuclear medicine to further improve methodologies and increase the number of tools to accelerate drug development. Var.

ISBN: 9789814317740 (electronic bk.)Subjects--Topical Terms:

550958
Drug Design.
Index Terms--Genre/Form:

542853
Electronic books.

LC Class. No.: RM301.25

Dewey Class. No.: 615.19

National Library of Medicine Call No.: QV 745

Trends on the role of PET in drug development
LDR:04370cmm a2200325Ia 4500 001 1901590
003 OCoLC
005 20140116093432.0
006 m d
007 cr |n|---|||||
008 140127s2012 si o 000 0 eng d
020 $a 9789814317740 (electronic bk.)
020 $a 9814317748 (electronic bk.)
020 $z 9789814317733
035 $a ocn794328395
040 $a EBLCP $b eng $c EBLCP $d OCLCQ $d YDXCP $d OHS $d N $d OCLCQ
050 4 $a RM301.25
060 4 $a QV 745
082 0 4 $a 615.19
100 1 $a Elsinga, Philip H. $3 2016942
245 1 0 $a Trends on the role of PET in drug development $h [electronic resource] / $c Philip H. Elsinga.
260 $a Singapore : $b World Scientific, $c 2012.
300 $a 1 online resource (799 p.)
500 $a 2.2 Influence of ionic liquid and tertiary alcohols on [18F]fluorination.
505 0 $a The Editors; Contributors; Preface; 1 Introduction on PET. Description of Basics and Principles Aren van Waarde; References; 2 Drug Development in the Pharmaceutical Industry Adrian D. Nunn; 1. Introduction; 2. Drug Approval Rates; 3. Costs of Each Stage; 4. Efficiency of Drug Development; 5. Changing Healthcare Model; 6. Comparative Effectiveness; 7. Personalized Medicine; 8. Regulatory Issues; 9. Conclusions; References; 3 Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines R. Paul Maguire; 1. Summary.
505 8 $a 2. FDA Critical Path Initiative -- Drug Development Challenge3. Drug Development Process Decision Points; 3.1 Phases of drug development; 4. Imaging Biomarkers in General; 4.1 Imaging biomarkers for early decision making; 4.2 Diagnostics; 4.2.1 Smaller likelihood ratio; 4.3 Markers of disease; 5. Imaging Biomarkers Other than Molecular Imaging; 6. Biomarkers Other than Imaging; 7. Receptor Occupancy; 7.1 Determination of in vivo KD; 7.2 Typical RO study designs; 7.3 Assumptions; 8. Thresholds for Decision Making; 8.1 Efficacy and occupancy at G-coupled protein receptors.
505 8 $a 9. Sources of Imprecision9.1 Instrument sensitivity; 9.2 Variability of PK; 10. Safety of Molecular Imaging Probes; 11. Ideal Molecular Imaging Ligand; 11.1 Safety; 11.2 Affinity; 11.3 Non-specific binding; 11.4 Selectivity; 11.5 Easy deployment and implementation; 12. Models of PET-Pharmacokinetics -- Data Analysis; 13. Industry Academic Collaboration; 13.1 Labeling available chemical matter; 13.2 Translational imaging; 13.3 Customized therapies -- companion diagnostics; 14. Summary; References; 4 What is the Role of Positron Emission Tomography in Drug Development? Timothy J. McCarthy.
505 8 $a 1. Introduction2. Biomarker Definitions; 3. PET as a Tool for Proof of Target; 4. PET as a Tool for Proof of Mechanism; 5. PET as a Tool for Proof of Efficacy; 6. Summary and Conclusions; References; 5 Review of 11C Preparations and Examples in Drug Development Farhad Karimi and Bengt Långstrom; 1. Choice of Radionuclide; 2. 11C Compounds; 2.1 11C precursor; 2.2 11C chemistry based on [11C]methyl iodide/triflate; 2.2.1 Palladium-mediated C-C bond formation; 2.3 11C Chemistry based on [11C]carbon monoxide; 2.3.1 [11C]Carbon monoxide insertion.
505 8 $a 2.3.2 Organo metals mediated 11C-carbonylation reaction2.3.2.1 Palladium-mediated 11C-carbonylation reaction; 2.3.2.2 Selenium-mediated 11C-carbonylation reaction; 2.3.2.3 Rhodium-mediated 11C-carbonylation reaction; 2.3.2.4 Radical-mediated carbonylation reactions; 3. Endogenous PET-Radiopharmaceuticals; 4. Automated Synthetic Devices; References; 6 The Role of Recent Development of 18F Radiochemistry in Drug Development Farhad Karimi and Bengt Långstrom; 1. Introduction; 2. Nucleophilic 18F Fluorination; 2.1 Basic chemistry.
520 $a Drug development is very expensive and a fight against time. PET offers possibilities to speed up this process by adding unique in vivo information on pharmacokinetics/dynamics of a drug at an early stage. This information can help decision makers to move the drug in the drug development process or to decide to stop further developments. This unique and complete book highlights the different ways PET can be used and describes the latest trends in the various disciplines within nuclear medicine to further improve methodologies and increase the number of tools to accelerate drug development. Var.
588 $a Description based on print version record.
650 2 $a Drug Design. $3 550958
650 2 $a Technology, Pharmaceutical. $3 702084
650 2 $a Positron-Emission Tomography. $3 2016945
650 0 $a Drug development. $3 716904
650 0 $a Tomography, Emission. $3 554356
650 0 $a Pharmaceutical technology. $3 562441
655 4 $a Electronic books. $2 lcsh $3 542853
700 1 $a Van Waarde, Aren. $3 2016943
700 1 $a Paans, Anne M. J. $3 2016944
856 4 0 $u http://www.worldscientific.com/worldscibooks/10.1142/7851#t=toc